-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH-EHA Joint Symposium: Failure of Targeted Cellular Immunotherapy and Hematopoietic Cell Transplant: Mechanisms and Mitigating Strategies

PhD Trainee
Program: General Sessions
Sunday, December 6, 2020: 9:30 AM-10:30 AM
Co-chairs:
Stephanie J. Lee, MD, MPH, President, American Society of Hematology, Clinical Research Division, Fred Hutchinson Cancer Research Center and John G. Gribben, MD, DSc, FRCP, FMedSci, FRCPath, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London
Disclosures:
Lee: Incyte: Consultancy, Research Funding; Amgen: Research Funding; Kadmon: Research Funding; Novartis: Research Funding; Pfizer: Consultancy, Research Funding; Syndax: Research Funding; Takeda: Research Funding; AstraZeneca: Research Funding. Gribben: TG Therapeutics: Consultancy, Honoraria; Abbvie: Honoraria; AstraZeneca: Honoraria, Research Funding; Morphosys: Honoraria; Novartis: Honoraria; Gilead: Honoraria; Janssen: Honoraria, Research Funding; Celgene: Research Funding.
North American Perspective: Targeted Cellular Immunotherapy

Crystal L. Mackall, MD

National Cancer Institute, NIH, Stanford, CA
European Perspective: Hematopoietic Cell Transplant

Luca Vago, MD, PhD

Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy; Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy
See more of: General Sessions
<< Previous Session | Next Session >>